Onconetix, Inc. Proceeds from License Fees Received
Onconetix, Inc. (ONCO) reported Proceeds from License Fees Received of $100.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLicenseFeesReceived · last filed 2026-05-13
- Onconetix, Inc. proceeds from license fees received for the quarter ending 2026-03-31 was $100.00K.
- Onconetix, Inc. proceeds from license fees received for the quarter ending 2022-12-31 was $2.50K.
- Onconetix, Inc. proceeds from license fees received for the quarter ending 2022-09-30 was $2.50K.
- Onconetix, Inc. proceeds from license fees received for the quarter ending 2022-06-30 was -$217.50K.
- Onconetix, Inc. proceeds from license fees received for fiscal 2025 was $100.00K.
- Onconetix, Inc. proceeds from license fees received for fiscal 2023 was $100.00K.
- Onconetix, Inc. proceeds from license fees received for fiscal 2021 was $225.00K.
| Period end | Proceeds from License Fees Received 3 month | Proceeds from License Fees Received 6 month | Proceeds from License Fees Received 9 month | Proceeds from License Fees Received 12 month |
|---|---|---|---|---|
| 2026-03-31 | $100.00K 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $100.00K 10-K · filed 2026-03-13 | |||
| 2023-12-31 | $100.00K 10-K · filed 2024-04-11 | |||
| 2022-12-31 | $2.50K derived: 10-Q 12 month − 10-Q 9 month · filed 2023-05-12 | $5.00K derived: sum of 2 quarters · filed 2023-05-12 | -$212.50K derived: sum of 3 quarters · filed 2023-05-12 | $15.00K 10-Q · filed 2023-05-12 |
| 2022-09-30 | $2.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$215.00K derived: sum of 2 quarters · filed 2022-11-14 | $12.50K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$217.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $10.00K 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | $227.50K 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | $225.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |